CSB 2.25 CSB 2.25  Addition of remifentanil to schedule II; transfer of dronabinol from schedule II to schedule III; addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil.

CSB 2.25(1) (1) Section 961.16 (3) (cm), Stats., is amended to read:

(cm) Carfentanil;

CSB 2.25(2) (2) Section 961.16 (3) (xm), Stats., is created to read:

(xm) Remifentanil;

CSB 2.25(3) (3) Section 961.16 (10) (a), Stats., is repealed.

CSB 2.25(4) (4) Section 961.18 (4m), Stats., is created to read:

(4m) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6aR-trans)-6a, 7, 8, 10a-tetrahydro-6, 6. 9-trimethyl-3-pentyl-6H-dibenzo(b, d)pyran-1-ol, and (-)-delta-9-(trans)-tetrahydrocannabinol.)

CSB 2.25(5) (5) Section 961.20 (2) (o) and (p), Stats., is created to read:

(o) Zaleplon.

(p) Zolpidem.

CSB 2.25(6) (6) Section 961.20 (2m) (at), (bu) and (f), Stats., is created to read:

(at) Fenproporex.

(bu) Modafinil.

(f) Sibutramine.

CSB 2.25 History History: Cr. Register, July, 2000, No. 535, eff. 8-1-00.

CSB 2.26 CSB 2.26  Addition of dihydroetorphine to schedule II.

CSB 2.26(1) (1) Section 961.16 (2) (a) 4r., Stats., is created to read:

4r. Dihydroetorphine.

CSB 2.26 History History: CR 01-071: Cr. Register November 2001 No. 551, eff. 12-1-01.

CSB 2.28 CSB 2.28  Addition of dichloralphenazone to schedule IV.

CSB 2.28(1) (1) Section 961.20 (2) (cs), Stats., is created to read:

Section 961.20 (2) (cs) Dichloralphenazone;

CSB 2.28 History History: CR 02-025: Cr. Register October 2002 No. 562, eff. 11-1-02.

CSB 2.29 CSB 2.29  Transfer of buprenorphine from schedule V to schedule III.

CSB 2.29(1) (1) Section 961.18 (5m), Stats., is created to read:

Section 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:

(a) Buprenorphine

CSB 2.29 History History: CR 03-056: cr. Register January 2004 No. 577, eff. 2-1-04.

CSB 2.30 CSB 2.30  Addition of gamma-hydroxybutyric acid to schedule III.

CSB 2.30(1) (1) Section 961.18 (3) (o), Stats., is created to read:

Section 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act:

1. Gamma-hydroxybutyric acid.

CSB 2.30 History History: CR 03-057: cr. Register January 2004 No. 577, eff. 2-1-04.

CSB 2.31 CSB 2.31  Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I.

CSB 2.31(1) (1) Section 961.14 (4) (wh), Stats., is created to read:

Section 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as "2C-T-7";

CSB 2.31 History History: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07.

CSB 2.32 CSB 2.32  Addition of N- benzylpiperazine (BZP) to schedule I.

CSB 2.32(1) (1) Section 961.14 (7) (q), Stats., is created to read:

Section 961.14 (7) (q) N - benzylpiperazine, commonly known as "BZP."

CSB 2.32 History History: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07.

CSB 2.33 CSB 2.33  Addition of alpha-methyltryptamine (AMT) to schedule I.

CSB 2.33(1) (1) Section 961.14 (4) (wi), Stats., is created to read:

Section 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as "AMT";

CSB 2.33 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.

CSB 2.34 CSB 2.34  Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).

CSB 2.34(1) (1) Section 961.14 (4) (wj), Stats., is created to read:

Section 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as "5-MeO-DIPT";

CSB 2.34 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.

CSB 2.35 CSB 2.35  Addition of lisdexamfetamine to schedule II.

CSB 2.35(1) (1) Section 961.16 (5) (e), Stats., is created to read:

Section 961.16 (5) (e) Lisdexamfetamine, commonly known as "Vyvanse TM."

CSB 2.35 History History: CR 10-112: cr. Register April 2011 No. 664, eff. 5-1-11.